SFG
CBIO

SevenBridge Financial Group’s Crescent Biopharma CBIO Stock Holding History

SevenBridge Financial Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5
Closed -$6K – 310
2019
Q2 		$6K Hold
5
– – ﹤0.01% 502
2019
Q1 		$6K Hold
5
– – ﹤0.01% 461
2018
Q4 		$5K Hold
5
– – ﹤0.01% 444
2018
Q3 		$7K Hold
5
– – ﹤0.01% 453
2018
Q2 		$8K Hold
5
– – ﹤0.01% 446
2018
Q1 		$8K Buy
+5
New +$10.4K ﹤0.01% 449

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

SevenBridge Financial Group's CBIO Position: Q3 2019 in Review

SevenBridge Financial Group sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 5 shares — an estimated $6K sold.

SevenBridge Financial Group first reported a position in CBIO in Q1 2018 and held it in 6 quarters. The position peaked at $8K in Q2 2018. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

  • SevenBridge Financial Group reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
  • SevenBridge Financial Group sold 5 Crescent Biopharma shares in Q3 2019, an estimated $6K.
  • SevenBridge Financial Group first reported a position in Crescent Biopharma in Q1 2018 and held it in 6 quarters.
  • SevenBridge Financial Group's Crescent Biopharma position peaked at $8K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on SevenBridge Financial Group's 13F filing for Q3 2019, filed 9 Oct 2019.